Pharmacokinetics and effects of aminorex in horses

American Journal of Veterinary Research

Volumn 69, Issue 5, 2008, Pages 675-681

  Soma, Lawrence R ^a   Rudy, Jeffrey A ^b   Uboh, Cornelius E ^b   Xu, Fran ^a   Snapp, Heidi M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; KIDNEY CLEARANCE; MALE; NONHUMAN; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; AMINOREX; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HORSES; INFUSIONS, INTRAVENOUS; MALE; RANDOM ALLOCATION;

ANIMALIA; EQUIDAE;

EID: 44349168225     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.5.675     Document Type: Article

References (32)

1. Poos GI, Carson JR, Rosenau JD, et al. 2-Amino-5-aryl-2-oxazolines. Potent new anorectic agents. J Med Chem 1963;6: 266-272.
2. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985;27:160-171.
3. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001;321:292-299.
4. Russell BR, Beresford RA, Schmierer DM, et al. Stimulus properties of some analogues of 4-methylaminorex. Pharmacol Biochem Behav 1995;51:375-378.
5. Brewster ME, Davis FT. Appearance of aminorex as a designer analog of 4-methylaminorex. J Forensic Sci 1991;36:587-592.
6. Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 1999;99:156-161.
7. Sato N, Nakanishi N. Drug induced pulmonary hypertension [in Japanese]. Nippon Rinsho 2001;59:1197-1202.
8. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
9. Rothman RB, Ayestas MA, Dersch CM, et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999;100:869-875.
10. Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996;94:2216-2220.
11. Woolverton WL, Massey BW, Winger G, et al. Evaluation of the abuse liability of aminorex. Drug Alcohol Depend 1994;36: 187-192.
12. Young R. Aminorex produces stimulus effects similar to amphetamine and unlike those of fenfluramine. Pharmacol Biochem Behav 1992;42:175-178.
13. International Organization for Standardization (ISO). ISO/IEC international standard 17025: general requirements for the competence of testing and calibration laboratories. Geneva, Switzerland: International Organization for Standardization (ISO), 1999.
14. Boston RC, Greif PC, Bermn M. Conversational SAAM - an interactive program for kinetic analysis of biological systems. Comput Programs Biomed 1981;13:111-119.
15. Stefanovski D, Moate PJ, Boston C. WinSAAM: a windows based compartmental modeling system. Metabolism 2003;52:1153-1166.
16. Berman M, Schoenfeld R. Invariants in experimental data on linear kinetics and the formulation of models. J Appl Phys 1965;27:1361-1370.
17. Wastney ME, Patterson BH, Linares OA, et al. WinSAAM. Investigating biological systems using modeling: strategies and software. New York: Academic Press Inc, 1999;129.
18. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts & applications. 3rd ed. Stockholm: Swedish Pharmaceutical Press, 2000;81-82.
19. Baggot JD. Principles of drug disposition in domestic animals: the basis of veterinary clinical pharmacology. Philadelphia: WB Saunders Co, 1977;170-171.
20. Powers J. Statistical analysis of pharmacokinetic data. J Vet Pharmacol Ther 1990;13:113-120.
21. Glennon RA, Misenheimer B. Stimulus properties of a new designer drug: 4-methylaminorex ("U4Euh"). Pharmacol Biochem Behav 1990;35:517-521.
22. Gaine SP, Rubin LJ, Kmetzo JJ, et al. Recreational use of aminorex and pulmonary hypertension. Chest 2000;118:1496-1497.
23. Brunner HR, Stepanek J. Blood pressure increase in the pulmonary circulation of the dog caused by aminorex. Naunyn Schmiedebergs Arch Pharmacol 1970;266:304-305.
24. Will JA, Bisgard GE, et al. Haemodynamic effects of oral aminorex and amphetamine in unanaesthetized beagle dogs. Thorax 1972; 27:120-126.
25. Stepanek J, Zak F. Two-year peroral administration of aminorex in the dog [in German]. Z Kardiol 1975;64:768-781.
26. Orr JA, Ungerer T, Seavey E, et al. Hemodynamic effects of long term feeding of sympathomimetic amines to swine. J Environ Pathol Toxicol 1978;1:911-925.
27. Mlczoch J, Weir EK, Reeves JT, et al. Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation in the pig. Basic Res Cardiol 1979;74:313-320.
28. Smith P, Heath D, Kay JM, et al. Pulmonary arterial pressure and structure in the patas monkey after prolonged administration of aminorex fumarate. Cardiovasc Res 1973;7:30-38.
29. Leuschner F, Otto H, Wagener HH, et al. Tolerance to aminorex and some other compounds during prolonged administration to beagle dogs. Naunyn Schmiedebergs Arch Pharmacol 1970;266:391-392.
30. Kay JM, Smith P, Heath D, et al. Aminorex and the pulmonary circulation. Thorax 1971;26:262-270.
31. Byrne-Quinn E, Grover RF. Aminorex (Menocil) and amphetamine: acute and chronic effects on pulmonary and systemic haemodynamics in the calf. Thorax 1972;27:127-131.
32. Mayhew IG. Large animal neurology; a hand book for veterinarian clinicians. Philadelphia: Lea & Febiger Co, 1989;114-115.